The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one ...

The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy. The FDA approved daraxonrasib (Rasonque; Revolution ...

The FDA has approved the first RAS-targeted therapy for metastatic pancreatic cancer, offering a new treatment option for patients with previously treated disease. Daraxonrasib (Rasonque, Revolution ...

Dictado por el prestigioso profesional Ing. Héctor Daniel Farías, el curso está dirigido a profesionales de la Ingeniería Civil, Vial, Hidráulica, Construcciones y disciplinas conexas, técnicos en ...

El Machine Learning o “Aprendizaje automático” dota a las computadoras con capacidades para ejecutar tareas que los humanos realizan de forma ineficiente. Cada vez son más las empresas que demandan ...

b RAS G12, G13 or Q61 mut or no RAS mut identified. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting II. This abstract does not include a full text component.

Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, with ...

Kestrel today announced that the first patient has been dosed in its phase 1 trial of KST-6051, an oral small molecule meant to inhibit multiple different kinds of KRAS mutations. (iStock / Getty ...

AACR was full of biotechs showcasing their preclinical Ras candidates, including Clasp Therapeutics, Verastem Oncology and BlossomHill Therapeutics. (Darren Incorvaia) After dropping headline-grabbing ...

Add the following CSS to the header block of your HTML document. Then add the mark-up below to the body block of the same document. .videoWrapper { position: relative; padding-bottom: 56.25%; ...